MGNX
MACROGENICS INCPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 28 ▲ Three major institutional investors, Morgan Stanley, Wells Fargo, an…
- Apr 8 ▲ MacroGenics announced that the FDA has lifted the partial clinical h…
- May 11 MacroGenics is selling its GMP drug substance manufacturing operatio…
- May 12 ▲ MacroGenics entered into a definitive agreement to sell its GMP manu…
- May 13 ▲ MacroGenics reported Q1 2026 revenue of $20.8M (up 57% YoY) and net…
- May 17 Trial readout: Results Pending: lorigerlimab (Phase 2), Completed 87d ago
- Jun 12 A mixed institutional cluster formed in MGNX during Q3 2024: 5 small…
- Jul 2 ▲ MacroGenics completed the sale of its GMP manufacturing operations t…
- Aug 19 ▼ 1 insider sell $129.1K at $4.15
- Oct 15 ▲ Short interest falls 28.1% to 5.06M
- Oct 23 ▲ MacroGenics reported positive interim Phase 1 data for MGC026, a B7-…
- Oct 26 ▲ MacroGenics announced positive interim Phase 2 LINNET data for lorig…
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $129.1K.
- InstitutionsMIXED
Q3 2026: 14 added (0 new), 15 trimmed or exited.
- Short sellersSTEADY
Short interest −2.2% to 4.95M shares. 3.9 days to cover, ≈7.8% of shares.
- TrendDOWNTREND
34% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Oct 26.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| BlackRock, Inc. | ADD | $23.7M |
| WASATCH ADVISORS LP | TRIM | $4.9M |
| STATE STREET CORP | ADD | $4.5M |
| FMR LLC | DOUBLED | $1.6M |
| Nuveen, LLC | ADD | $750.9K |
| STRS OHIO | ADD | $688.6K |
| Russell Investments Group, Ltd. | DOUBLED | $557.0K |
| MORGAN STANLEY | ADD | $458.2K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
Last action Aug 2026Price is below the lowest target. Median implies +292%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Aug 17, 2026 | B. Riley Securities MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Kuriakose Emil Director Oct 30, 2026 | AWARD | 7,500 sh |
Kuriakose Emil Director Oct 30, 2026 | AWARD | 44,000 sh |
VASCONCELLES MICHAEL Director Oct 30, 2026 | AWARD | 44,000 sh |
VASCONCELLES MICHAEL Director Oct 30, 2026 | AWARD | 7,500 sh |
Bonvini Ezio Sr VP, Research & CSO Oct 6, 2026 | EXERCISE | $20.8K |
Peters Jeffrey Stuart Senior VP, GC, and Secretary Aug 19, 2026 | SELL | $129.1K |
Bonvini Ezio Sr VP, Research & CSO Aug 17, 2026 | EXERCISE | $104.0K |
Koenig Scott Director May 19, 2026 | AWARD | 22,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
16 filings · 5 press releases · 5 bullish · 1 bearish · 1 mixed · 9 neutral- NEUTRAL SC 13G/ANov 16, 2026
Armistice Capital LLC filed an amended Schedule 13G disclosing a 9.42% passive stake in MacroGenics as of September 30, 2026, representing 6,000,000 shares. This is an increase from the prior filing, but the filing is routine for a passive investor and does not indicate activist intent.
🔒 Fresh report (last 24h), subscribers only
- NEUTRAL 8-KNov 13, 2026
MacroGenics posted a corporate presentation on its website with updated clinical data for its…
Monitor next MGC026 data update expected mid-2027 and enrollment progress in SCCHN monotherapy cohort and lorigerlimab CCGC cohort by YE2026. The company's cash runway through 2028 reduces near-term…
- BEARISH PRESS-RELEASENov 12, 2026
MacroGenics reported Q3 2026 revenue of $18.7M, well below the $39.2M consensus, and a GAAP net…
The significant revenue miss and wider-than-expected net loss are likely to pressure the stock near-term. Monitor upcoming clinical data readouts for MGC028 and MGC026 in H1 2027, as pipeline…
- NEUTRAL 3Nov 3, 2026
Michael Vasconcelles filed a Form 3 initial statement of beneficial ownership with MacroGenics…
Routine initial ownership filing with no shares reported. Monitor future Form 4 filings for any subsequent open-market purchases or grants that would indicate insider conviction.
All MGNX filing & press-release reports (21)
- SC 13G/A reportNov 16, 2026
- 8-K reportNov 13, 2026
- PRESS-RELEASE reportNov 12, 2026
- 3 reportNov 3, 2026
- 3 reportNov 3, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportOct 26, 2026
- 8-K reportOct 23, 2026
- 144 reportOct 22, 2026
- PRESS-RELEASE reportOct 15, 2026
- 8-K reportJul 8, 2026
- PRESS-RELEASE reportJul 2, 2026
- INST-CLUSTER reportJun 12, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 13, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 11, 2026
- 8-K reportApr 8, 2026
- PRESS-RELEASE reportApr 8, 2026
- DEFA14A reportApr 8, 2026
- INST-CLUSTER reportFeb 28, 2026